Personalised Approach to Anticoagulation

Abstract

Get full access to this article

View all access options for this article.

References

Kinsella

, James

. Guidelines in the era of realistic medicine. J R Coll Physicians 2016; 46: 74–6. http://dx.doi.org/10.4997/jrcpe.2016.201

Bashir

, Al-Mohammed

, Gupta

. A practical approach to the new oral anticoagulants used for stroke prevention in patients with atrial fibrillation. J R Coll Physicians 2016; 46: 113–8. http://dx.doi.org/10.4997/jrcpe.2016.211

Kmietowicz

. Boehringer Ingelheim withheld safety analyses on new anticoagulant, The BMJ investigation finds. BMJ 2014; 349:g4756. http://dx.doi.org/10.1136/bmj.g4756

Moore

, Cohen

, Mattison

. Dabigatran, bleeding, and the regulators. BMJ 2014; 349:g4517. http://dx.doi.org/10.1136/bmj.g4517

Cohen

. Rivaroxaban: can we trust the evidence? BMJ 2016; 352:i575. http://dx.doi.org/10.1136/bmj.i575

Pirmohamed

, Burnside

, Eriksson

. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 2013; 369: 2294–303. http://dx.doi.org/10.1056/NEJMoa1311386

Aithal

, Day

, Kesteven

, Daly

. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717–9.

D'Andrea

, Di Perna

. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105: 645–9.

Klein

, Altman

, Eriksson

. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753–64. http://dx.doi.org/10.1056/NEJMoa0809329

10.

Kimmel

, French

, Kasner

. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 2013; 369: 2283–93. http://dx.doi.org/10.1056/NEJMoa1310669